Literature DB >> 23774274

LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes.

B Eliasson1, S Gudbjörnsdottir1, B Zethelius2, K Eeg-Olofsson1, J Cederholm3.   

Abstract

AIMS: We assessed the association between different blood lipid measures and risk of fatal/nonfatal coronary heart disease (CHD), which has been less analysed previously in type 2 diabetes. DESIGN,
METHODS: Observational study of 46,786 patients with type 2 diabetes, aged 30-70 years, from the Swedish National Diabetes Register, followed for a mean of 5.8 years until 2009. Baseline and updated mean low-density lipoprotein (LDL)-, high-density lipoprotein (HDL)-, non-HDL-cholesterol, and non-HDL-to-HDL-cholesterol ratio were measured.
RESULTS: Hazard ratios (HR) for CHD with quartiles 2-4 of baseline lipid measures, with lowest quartile 1 as reference: 1.03-1.29-1.63 for LDL; 1.23-1.41-1.95 for non-HDL; 1.29-1.39-1.57 for HDL; and 1.31-1.67-2.01 for non-HDL:HDL, all p < 0.001 except for quartile 2 of LDL, when adjusted for clinical characteristics and nonlipid risk factors. A similar picture was seen with updated mean values. Splines with absolute 6-year CHD rates in a Cox model showed decreasing rates only down to around 3 mmol/l for LDL, with linearly decreasing rates to the lowest level of non-HDL:HDL. Non-HDL and HDL were independent additive risk factors for CHD risk. HRs per 1 SD continuous decrease in baseline or updated mean HDL were 1.14-1.17 when fully adjusted as above, and 1.08-1.13 when also adjusted for non-HDL (p < 0.001). HRs were 1.13-1.16 adjusted for LDL, and 1.22-1.26 adjusted for total cholesterol and triglycerides (p < 0.001). Splines showed progressively increasing 6-year CHD rates with lower HDL down to 0.5 mmol/l.
CONCLUSIONS: This study suggests that lower levels of non-HDL:HDL are a better risk marker for CHD than LDL-cholesterol below 3 mmol/l.
© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Diabetes mellitus; LDL-cholesterol; coronary heart disease; epidemiology; human; lipoproteins; non-HDL-cholesterol

Mesh:

Substances:

Year:  2013        PMID: 23774274     DOI: 10.1177/2047487313494292

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  17 in total

1.  Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR).

Authors:  Björn Zethelius; Soffia Gudbjörnsdottir; Björn Eliasson; Katarina Eeg-Olofsson; Ann-Marie Svensson; Jan Cederholm
Journal:  Diabetologia       Date:  2015-06-19       Impact factor: 10.122

2.  Circulating growth differentiation factor 15 levels and apolipoprotein B to apolipoprotein A1 ratio in coronary artery disease patients with type 2 diabetes mellitus.

Authors:  Yufeng Mei; Zhiming Zhao; Yongnan Lyu; Yan Li
Journal:  Lipids Health Dis       Date:  2022-07-16       Impact factor: 4.315

3.  Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients.

Authors:  Ariella De Monte; Davide Brunetti; Luigi Cattin; Francesca Lavanda; Erica Naibo; Maria Malagoli; Giorgio Stanta; Serena Bonin
Journal:  Mol Clin Oncol       Date:  2018-01-11

4.  Comparison of percentage body fat and body mass index for the prediction of inflammatory and atherogenic lipid risk profiles in elderly women.

Authors:  Silvana Schwerz Funghetto; Alessandro de Oliveira Silva; Nuno Manuel Frade de Sousa; Marina Morato Stival; Ramires Alsamir Tibana; Leonardo Costa Pereira; Marja Letícia Chaves Antunes; Luciano Ramos de Lima; Jonato Prestes; Ricardo Jacó Oliveira; Maurílio Tiradentes Dutra; Vinícius Carolino Souza; Dahan da Cunha Nascimento; Margô Gomes de Oliveira Karnikowski
Journal:  Clin Interv Aging       Date:  2015-01-13       Impact factor: 4.458

5.  Non-High-Density Lipoprotein Cholesterol Levels on the Risk of Asymptomatic Intracranial Arterial Stenosis: A Result from the APAC Study.

Authors:  Jianwei Wu; Anxin Wang; Xin Li; Shouling Wu; Xingquan Zhao
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

6.  Trends in lipid profiles and descriptive characteristics of U.S. adults with and without diabetes and cholesterol-lowering medication use-National Health and Nutrition Examination Survey, 2003-2012, United States.

Authors:  Carla I Mercado; Edward Gregg; Cathleen Gillespie; Fleetwood Loustalot
Journal:  PLoS One       Date:  2018-03-06       Impact factor: 3.240

7.  Hypolipidemic, Hepatoprotective and Renoprotective Effects of Cydonia Oblonga Mill. Fruit in Streptozotocin-Induced Diabetic Rats.

Authors:  Mansur Mirmohammadlu; Seyed Hojjat Hosseini; Mohammad Kamalinejad; Majid Esmaeili Gavgani; Maryam Noubarani; Mohammad Reza Eskandari
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

8.  Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.

Authors:  Paul Valensi; Antoine Avignon; Ariane Sultan; Bernard Chanu; Minh Tuan Nguyen; Emmanuel Cosson
Journal:  Cardiovasc Diabetol       Date:  2016-07-22       Impact factor: 9.951

9.  The effects of seed from Linum usitatissimum cultivar with increased phenylpropanoid compounds and hydrolysable tannin in a high cholesterol-fed rabbit.

Authors:  Bożena Króliczewska; Dorota Miśta; Angelika Ziarnik; Magdalena Żuk; Jan Szopa; Ewa Pecka-Kiełb; Wojciech Zawadzki; Jarosław Króliczewski
Journal:  Lipids Health Dis       Date:  2018-04-10       Impact factor: 3.876

10.  Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.

Authors:  Sofia Axia Karlsson; Stefan Franzén; Ann-Marie Svensson; Mervete Miftaraj; Björn Eliasson; Karolina Andersson Sundell
Journal:  BMC Health Serv Res       Date:  2018-11-28       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.